Kaken Pharmaceutical Co's market cap is currently $1.11B. The company's EPS TTM is $3.601; its P/E ratio is 8.14; and it has a dividend yield of 4.35%. Kaken Pharmaceutical Co is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Income Statement
Total Revenue	¥ 72.04B	¥ 72.98B	¥ 76.03B	¥ 74.98B	¥ 89.23B
Gross Profit	¥ 38.54B	¥ 39.56B	¥ 41.58B	¥ 40.91B	¥ 50.48B
Operating Income	¥ 9.51B	¥ 8.00B	¥ 17.06B	¥ 17.79B	¥ 26.51B
EBITDA	¥ 12.57B	¥ 10.57B	¥ 16.38B	¥ 20.11B	¥ 29.37B
Net Income	¥ 8.03B	¥ 5.44B	¥ 9.55B	¥ 13.40B	¥ 19.37B
Balance Sheet
Cash & Short-Term Investments	¥ 65.32B	¥ 74.26B	¥ 74.62B	¥ 77.31B	¥ 73.32B
Total Assets	¥ 171.62B	¥ 166.33B	¥ 165.18B	¥ 163.33B	¥ 157.88B
Total Debt	¥ 3.85B	¥ 3.85B	¥ 3.85B	¥ 3.85B	¥ 3.85B
Net Debt	¥ -46.77B	¥ -55.71B	¥ -57.17B	¥ -59.86B	¥ -55.87B
Total Liabilities	¥ 27.87B	¥ 29.49B	¥ 26.86B	¥ 27.08B	¥ 29.41B
Stockholders' Equity	¥ 143.75B	¥ 136.26B	¥ 137.75B	¥ 136.26B	¥ 128.47B
Cash Flow
Free Cash Flow	¥ 410.00M	¥ 7.05B	¥ 10.08B	¥ 12.09B	¥ 25.27B
Operating Cash Flow	¥ 2.58B	¥ 9.25B	¥ 13.34B	¥ 14.38B	¥ 27.47B
Investing Cash Flow	¥ -5.85B	¥ -2.63B	¥ -7.89B	¥ -1.64B	¥ -2.53B
Financing Cash Flow	¥ -5.66B	¥ -6.99B	¥ -8.13B	¥ -8.75B	¥ -10.17B

Currency in JPY

Kaken Pharmaceutical Co Earnings and Revenue History

Income Statement >

Kaken Pharmaceutical Co Debt to Assets

Balance Sheet >

Kaken Pharmaceutical Co Cash Flow

Cash Flow >

Kaken Pharmaceutical Co Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing